Hopes that anti-tau drugs could emerge as treatments for Alzheimer’s have been dented by the failure of a phase 2b trial of J&J’s posdinemab.
Following Abivax, Formation Bio licenses miR-124 drug from China
The French biotech Abivax was a biotech market standout for 2025. Formation Bio now wants a piece of that success. The privately-held New York pharma
